Clinical trials: Advanced Tumor
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NKTR-214 (NCT02869295)
- Testing
- NKTR-214
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Nektar Therapeutics
Breast Cancer, Stage IV Breast Cancer
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid…
- Trial name
- NCT01093612
- Testing
- positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer, Lung Cancer
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
Nivolumab releases the inhibition of the immune system against human cancers. Dramatic and sustained activity has been observed in advanced lung cancer. Ablation may stimulate the immune system by exposing new tumor antigens.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
- Trial name
- NCT02469701
- Testing
- nivolumab and ablation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- howard safran
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previously treated with combination chemotherapy that included cisplatin or…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00638937
- Testing
- saracatinib
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Stage IIIB Breast Cancer
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and bevacizumab and to see how well they work in treating patients with metastatic breast cancer and/or breast…
- Conditions
- Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00368875
- Testing
- vorinostat, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Cancer
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Lorlatinib is a third-generation, oral, reversible, ATP-competitive, macrocyclic TKI of ALK and ROS1. Lorlatinib was specifically designed to penetrate the CNS and to overcome known secondary resistance mutations in the ALK…
- Trial name
- NCT04541706
- Testing
- Lorlatinib
- Where
- 12 sites in India
- Volunteers
- 100 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC.
- Trial name
- NCT01846416
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
- Where
- 31 sites in United States, Belgium and 3 more
- Volunteers
- 138 people
- Sponsor
- Genentech, Inc.
Melanoma
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
- Trial name
- NCT04370704
- Testing
- INCAGN02385, INCAGN02390, INCMGA00012.
- Where
- 17 sites in United States, Australia
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Breast Cancer
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).
- Trial name
- NCT01047358
- Testing
- Aromasin
- Where
- 22 sites in South Korea
- Volunteers
- 206 people
- Sponsor
- Pfizer
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
The trial objective will be to evaluate whether BI 6727 monotherapy or in combination with pemetrexed may be effective in the treatment of advanced or metastatic NSCLC in patients who relapsed after or failed first-line platinum…
- Trial name
- NCT00824408
- Testing
- pemetrexed, BI 6727
- Where
- 12 sites in Canada, The Bahamas
- Volunteers
- 143 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Lymphomas
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days…
- Trial name
- NCT01512758
- Testing
- Alisertib
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
- Trial name
- NCT00861614
- Testing
- Ipilimumab
- Where
- 158 sites in United States, Argentina and 25 more
- Volunteers
- 988 people
- Sponsor
- Bristol-Myers Squibb
Adrenocortical Carcinoma
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
- Trial name
- NCT02673333
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
The safety and efficacy of combination of SBRT with sequential S-1 in treating patients with locally advanced pancreatic cancer and poor medical conditions will be evaluated.
- Trial name
- NCT02704143
- Testing
- combination of Cyberknife with S-1
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Changhai Hospital
ALK or ROS1-positive NSCLC
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.
- Trial name
- NCT03672643
- Testing
- Crizotinib
- Where
- 14 sites in China
- Volunteers
- 41 people
- Sponsor
- Pfizer
Hereditary Clear Cell Renal Cell Carcinoma, Kidney Cancer
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00727532
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Advanced Solid Tumor
MSC2015103B in Solid Tumors
The main purpose of this study is to test the experimental drug, MSC2015103B at different dose levels and on different treatment schedules, to see whether it is safe and can be tolerated when given to subjects once a day one day…
- Trial name
- NCT01453387
- Testing
- MSC2015103B
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Non-Small Cell Lung Cancer
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
This is a phase I/II study for previously untreated subjects with advanced NSCLC. The study will take place in two phases. First, a cohort of twelve participants will be enrolled in phase I part and will be treated with…
- Trial name
- NCT02382406
- Testing
- Carboplatin, Nab-paclitaxel, MK-3475 (Phase I)
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Nisha Mohindra, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.